BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: García-Sanz P, M F G Aerts J, Moratalla R. The Role of Cholesterol in α-Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease. Mov Disord 2021;36:1070-85. [PMID: 33219714 DOI: 10.1002/mds.28396] [Cited by in Crossref: 3] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Fernández-calle R, Konings SC, Frontiñán-rubio J, García-revilla J, Camprubí-ferrer L, Svensson M, Martinson I, Boza-serrano A, Venero JL, Nielsen HM, Gouras GK, Deierborg T. APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases. Mol Neurodegeneration 2022;17. [DOI: 10.1186/s13024-022-00566-4] [Reference Citation Analysis]
2 Hammel G, Zivkovic S, Ayazi M, Ren Y. Consequences and mechanisms of myelin debris uptake and processing by cells in the central nervous system. Cell Immunol 2022;:104591. [PMID: 36030093 DOI: 10.1016/j.cellimm.2022.104591] [Reference Citation Analysis]
3 Sanchez-Mirasierra I, Ghimire S, Hernandez-Diaz S, Soukup SF. Targeting Macroautophagy as a Therapeutic Opportunity to Treat Parkinson's Disease. Front Cell Dev Biol 2022;10:921314. [PMID: 35874822 DOI: 10.3389/fcell.2022.921314] [Reference Citation Analysis]
4 Xu X, Li Z, Zuo H, Chen H, Gui Y. Mesenchymal stem cell-derived exosomes altered neuron cholesterol metabolism via Wnt5a-LRP1 axis and alleviated cognitive impairment in a progressive Parkinson's disease model. Neurosci Lett 2022;787:136810. [PMID: 35870714 DOI: 10.1016/j.neulet.2022.136810] [Reference Citation Analysis]
5 Xue J, Zhu Y, Wei L, Huang H, Li G, Huang W, Zhu H, Duan R. Loss of Drosophila NUS1 results in cholesterol accumulation and Parkinson's disease-related neurodegeneration. FASEB J 2022;36:e22411. [PMID: 35695805 DOI: 10.1096/fj.202200212R] [Reference Citation Analysis]
6 Hong X, Guo W, Li S, Laranjo M. Lower Blood Lipid Level Is Associated with the Occurrence of Parkinson’s Disease: A Meta-Analysis and Systematic Review. International Journal of Clinical Practice 2022;2022:1-10. [DOI: 10.1155/2022/9773038] [Reference Citation Analysis]
7 Gegg ME, Menozzi E, Schapira AH. Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments. Neurobiology of Disease 2022;166:105663. [DOI: 10.1016/j.nbd.2022.105663] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
8 Avisar H, Guardia-Laguarta C, Surface M, Papagiannakis N, Maniati M, Antonellou R, Papadimitriou D, Koros C, Athanassiadou A, Przedborski S, Lerner B, Stefanis L, Area-Gomez E, Alcalay RN. Lipid level alteration in human and cellular models of alpha synuclein mutations. NPJ Parkinsons Dis 2022;8:52. [PMID: 35468903 DOI: 10.1038/s41531-022-00313-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Zheng W, Fan D. Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson’s Disease: Pathogenesis and Therapeutic Implications. Front Aging Neurosci 2022;14:851135. [DOI: 10.3389/fnagi.2022.851135] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Dou Y, Liu S, Li Y, Wu H, Chen H, Ji Y. Plasma Cholesterol Levels as Potential Nutritional Biomarkers for Lewy Body Dementia. J Alzheimers Dis 2022. [PMID: 35124646 DOI: 10.3233/JAD-215295] [Reference Citation Analysis]
11 Arbo BD, Schimith LE, Goulart dos Santos M, Hort MA. Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.174800] [Reference Citation Analysis]
12 Cui L, Zhang Q, Huang Y, Yang L, Zhang J, Jiang X, Jia J, Lv Y, Zhang D, Huang Y. Impaired Retrograde Transport Due to Lack of TBC1D5 Contributes to the Trafficking Defect of Lysosomal Cathepsins in Ischemic/Hypoxic Cardiomyocytes. Front Cardiovasc Med 2021;8:796254. [PMID: 35004909 DOI: 10.3389/fcvm.2021.796254] [Reference Citation Analysis]
13 Zhong J, Li M, Xu J, Dong W, Qin Y, Qiu S, Li X, Wang H. Roflupram attenuates α-synuclein-induced cytotoxicity and promotes the mitochondrial translocation of Parkin in SH-SY5Y cells overexpressing A53T mutant α-synuclein. Toxicol Appl Pharmacol 2022;436:115859. [PMID: 34990728 DOI: 10.1016/j.taap.2021.115859] [Reference Citation Analysis]
14 Pikuleva IA. Targeting cytochrome P450 46A1 and brain cholesterol 24-hydroxylation to treat neurodegenerative diseases. Explor Neuroprotective Ther 2021;1:159-72. [PMID: 35156102 DOI: 10.37349/ent.2021.00013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Lv Y, Xu B, Zhang X, Chen C, Gao Y, Li N. Association of serum cholesterol with Parkinson's disease in a cohort of statin-free individuals. Brain Behav 2021;:e32454. [PMID: 34894416 DOI: 10.1002/brb3.2454] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Pfrieger FW. Neurodegenerative Diseases and Cholesterol: Seeing the Field Through the Players. Front Aging Neurosci 2021;13:766587. [PMID: 34803658 DOI: 10.3389/fnagi.2021.766587] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
17 Gadhavi J, Patel M, Bhatia D, Gupta S. Neurotoxic or neuroprotective: Post-translational modifications of α-synuclein at the cross-roads of functions. Biochimie 2021:S0300-9084(21)00224-8. [PMID: 34582997 DOI: 10.1016/j.biochi.2021.09.012] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 D'Errico M, Parlanti E, Pascucci B, Filomeni G, Mastroberardino PG, Dogliotti E. The interplay between mitochondrial functionality and genome integrity in the prevention of human neurologic diseases. Arch Biochem Biophys 2021;710:108977. [PMID: 34174223 DOI: 10.1016/j.abb.2021.108977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]